Mequinol

Identification

Summary

Mequinol is a topical agent used in combination with tretinoin to treat solar lentigines.

Generic Name
Mequinol
DrugBank Accession Number
DB09516
Background

Mequinol is a phenol used in various applications. It is used as an inhibitor for acrylic monomers and acrylonitirles, as a stabilizer for chlorinated hydrocarbons and ethyl cellulose, as an ultraviolet inhibitor, as a chemical intermediate in the manufacture of antioxidants, pharmaceuticals, plasticizers, and dyestuffs 3. It is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment of solar lentigines.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 124.1372
Monoisotopic: 124.0524295
Chemical Formula
C7H8O2
Synonyms
  • 4-Methoxyphenol
  • Mequinol
External IDs
  • BMS-181158

Pharmacology

Indication

Mequinol is currently primarily available only as an active ingredient in combination products combined with tretinoin that are indicated for the treatment of solar lentigines and related hyperpigmented lesions resulting from chronic sun exposure Label.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Mequinol is in fact considered a melanocytotoxic chemical which when oxidized in melanocytes results in the formation of toxic entities like quinones 3. Such cytotoxic compounds subsequently have the potential to damage and destroy pigment cells, therefore causing skin depigmentation 3. In response, skin cells are naturally capable of protecting themselves against such cytotoxic agents with the help of endogenous intracellular glutathione and the detoxification action of glutathione S-transferase on the cytotoxic compounds 3. Regardless, it is consequently by way of this seemingly negative and damaging pharmacodynamic profile by which the mechanism of action of mequinol is sometimes described 3.

Mechanism of action

Solar lentigines and related hyperpigmented lesions are localized, pigmented, macular lesions of the skin, usually on the areas of the body which have been chronically exposed to sunlight Label. These lesions are characterized by increased numbers of active melanocytes and increased melanin production Label.

Although the mechanism of action of mequinol is not fully elucidated Label, when employed as an active ingredient in combination with other agents like tretinoin in skin depigmentation products, a synergy between a number of potential mechanisms is proposed.

Firstly, mequinol is in fact considered a melanocytotoxic chemical which when oxidized in melanocytes results in the formation of toxic compounds like quinones 3. Such cytotoxic agents are subsequently capable of damaging and destroying pigment cells, which results in skin depigmentation 3 of solar lentigines or other related hyperpigmented lesions. Nevertheless, skin cells are naturally capable of protecting themselves against such cytotoxic entities by endogenous intracellular glutathione (GSH) 3. This protection is elicited through the enzymatic action of glutathione S-transferase (GST), which is responsible for the conjugation of agents toxic to glutathione 3. Conversely, tretinoin has been observed to serve as a potent inhibitor of mammalian GSTs and to be capable of reducing the level of intracellular GSH in various cells 3. As a result, the combination of mequinol with tretinoin seemingly allows for a synergistic enhancement of a melanocytotoxic effect that involves the inhibition and impairment of GSH and GST cytoprotection 3.

Secondly, even though mequinol is a substrate for the enzyme tyrosinase and therefore acts as a competitive inhibitor of the formation of melanin precursors by way of tyrosinase facilitated reactions, the clinical significance of this action is unknown Label.

Absorption

The systemic exposure to mequinol was assessed in eight healthy subjects following two weeks of twice-daily topical treatment of a tretinoin and mequinol combination product Label. About dose of the product corresponding to about 37.3 ug/cm^2 of mequinol was applied to the subjects' backs Label. The mean Cmax for mequinol was 9.92 ng/mL (range between 4.22 and 23.62 ng/mL) and the Tmax was 2 hours (range between 1 to 2 hours) Label. The safety of mequinol in this combination formulation is supported by the low systemic exposures of the agent in the subjects 3.

Volume of distribution

The volume of distribution is one that suggests mequinol is distributed throughout the total body water, and intracellular concentrations are not expected to vary greatly from gross measurements 6.

Protein binding

Readily accessible data regarding the protein binding of mequinol is not available.

Metabolism

Urine samples from melanoma patients treated with mequinol were analyzed and various mequinol metabolites were identified, including 3,4-dihydroxyanisole, the two o-methyl derivatives 3-hydroxy-4-methoxyanisole and 4-hydroxy-3-methoxyanisole, and even hydroquinone which may have originated at least partly from mequinol 2. All these identified metabolites were excreted predominantly as sulphates and glucuronides - only a small portion of the substances were present in urine in an unconjugated form 2. Ultimately, the 3,4-dihydroxyanisole is considered the most important metabolite of mequinol 2.

Hover over products below to view reaction partners

Route of elimination

Mequinol is predominantly renally eliminated as its metabolites 4,2.

Half-life

Mequinol demonstrated an elimination half-life of 30 to 90 minutes following intravenous infusion of 5 or 10 grams/m^2 over 3 to 5 hours in melanoma patients; similar values were reported after intra-arterial infusion 4.

Clearance

Readily accessible data regarding the clearance of mequinol is not available. The use of mequinol containing products is typically indicated for topical use.

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

If a mequinol and tretinoin combination topical product is applied excessively, some potential adverse effects like marked redness, peeling of skin, discomfort, discoloration, or hypopigmentation may occur Label. Such products are not indicated for oral ingestion Label.

MSDS data reports that chronic exposure to a dose of 25 UMOL/L in humans can result in mutagenic effects like DNA inhibition in lymphocytes MSDS.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
SolageMequinol (20 mg/1mL) + Tretinoin (0.1 mg/1mL)SolutionTopicalStiefel Laboratories, Inc.2003-01-012010-11-30US flag
SolagéMequinol (2 % w/v) + Tretinoin (0.01 % w/v)SolutionTopicalGlaxosmithkline Inc2003-01-022014-03-04Canada flag

Categories

ATC Codes
D11AX06 — Mequinol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as methoxyphenols. These are compounds containing a methoxy group attached to the benzene ring of a phenol moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
Methoxyphenols
Direct Parent
Methoxyphenols
Alternative Parents
4-alkoxyphenols / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / 4-alkoxyphenol / Alkyl aryl ether / Anisole / Aromatic homomonocyclic compound / Ether / Hydrocarbon derivative / Methoxybenzene / Methoxyphenol / Monocyclic benzene moiety
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols, methoxybenzene (CHEBI:69441)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
6HT8U7K3AM
CAS number
150-76-5
InChI Key
NWVVVBRKAWDGAB-UHFFFAOYSA-N
InChI
InChI=1S/C7H8O2/c1-9-7-4-2-6(8)3-5-7/h2-5,8H,1H3
IUPAC Name
4-methoxyphenol
SMILES
COC1=CC=C(O)C=C1

References

General References
  1. Kumar CM, Sathisha UV, Dharmesh S, Rao AG, Singh SA: Interaction of sesamol (3,4-methylenedioxyphenol) with tyrosinase and its effect on melanin synthesis. Biochimie. 2011 Mar;93(3):562-9. doi: 10.1016/j.biochi.2010.11.014. Epub 2010 Dec 7. [Article]
  2. Pavel S, Holden JL, Riley PA: Metabolism of 4-hydroxyanisole: identification of major urinary excretory products. Pigment Cell Res. 1989 Sep-Oct;2(5):421-6. [Article]
  3. TOXNET: 4-methoxyphenol [Link]
  4. Drugs.com: Mequinol and Tretinoin (Topical) [Link]
  5. PucChem: Mequinol Fb [Link]
  6. ECHA: Mequinol [Link]
Human Metabolome Database
HMDB0029696
PubChem Compound
9015
PubChem Substance
347827871
ChemSpider
8665
RxNav
15080
ChEBI
69441
ChEMBL
CHEMBL544
ZINC
ZINC000000001684
PDBe Ligand
4KS
Wikipedia
Mequinol
PDB Entries
4z3g / 4z3h / 5k1m
FDA label
Download (155 KB)
MSDS
Download (54.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionTopical
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6353029No2002-03-052020-08-24US flag

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility36.1 mg/mLALOGPS
logP1.31ALOGPS
logP1.51ChemAxon
logS-0.54ALOGPS
pKa (Strongest Acidic)9.94ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.46 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity34.5 m3·mol-1ChemAxon
Polarizability12.76 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00du-9300000000-7365fadaa1b55aee92c0
GC-MS Spectrum - EI-BGC-MSsplash10-0ab9-3900000000-b24cf2309ebe14f7ea37
GC-MS Spectrum - EI-BGC-MSsplash10-05gi-8900000000-22bed3d3611c3a5cd0d6
GC-MS Spectrum - EI-BGC-MSsplash10-0ab9-3900000000-b406ffca43dc64f80356
GC-MS Spectrum - EI-BGC-MSsplash10-05fr-3900000000-5f100d415313d60a9ba0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0900000000-3d4bc54dec9d0d2bf71d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-1900000000-cd190cc17b12c804fb8d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0691-9200000000-f98954ef6d73d4d0fc19
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0900000000-3cb1894d95675088e7b2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0900000000-125ba3d5d60e387415e5
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9600000000-c374964c5ebd2e35933e

Drug created on November 30, 2015 19:10 / Updated on May 21, 2021 10:21